CalciMedica, Inc. (CALC)
CalciMedica, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $1.75, up 0.57% on the session, giving a market capitalisation of $5.5M. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of 0.0%. Its beta of 1.12 implies it has historically moved more than the broad market.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CalciMedica, Inc. is most often compared with the following Healthcare names: